Evaxion A/S (EVAX) Competitors $2.54 -0.13 (-4.87%) Closing price 03:52 PM EasternExtended Trading$2.50 -0.04 (-1.77%) As of 07:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock EVAX vs. NEUP, ME, ATHA, IBIO, MTVA, ALVR, SONN, NXTC, LPTX, and IMCCShould you be buying Evaxion A/S stock or one of its competitors? The main competitors of Evaxion A/S include Neuphoria Therapeutics (NEUP), 23andMe (ME), Athira Pharma (ATHA), iBio (IBIO), MetaVia (MTVA), AlloVir (ALVR), Sonnet BioTherapeutics (SONN), NextCure (NXTC), Leap Therapeutics (LPTX), and IM Cannabis (IMCC). These companies are all part of the "pharmaceutical products" industry. Evaxion A/S vs. Its Competitors Neuphoria Therapeutics 23andMe Athira Pharma iBio MetaVia AlloVir Sonnet BioTherapeutics NextCure Leap Therapeutics IM Cannabis Evaxion A/S (NASDAQ:EVAX) and Neuphoria Therapeutics (NASDAQ:NEUP) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, earnings, valuation, profitability, dividends, institutional ownership, analyst recommendations and media sentiment. Does the media favor EVAX or NEUP? In the previous week, Evaxion A/S had 2 more articles in the media than Neuphoria Therapeutics. MarketBeat recorded 3 mentions for Evaxion A/S and 1 mentions for Neuphoria Therapeutics. Neuphoria Therapeutics' average media sentiment score of 1.87 beat Evaxion A/S's score of 0.63 indicating that Neuphoria Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Evaxion A/S Positive Neuphoria Therapeutics Very Positive Do analysts rate EVAX or NEUP? Evaxion A/S presently has a consensus target price of $10.00, suggesting a potential upside of 293.70%. Neuphoria Therapeutics has a consensus target price of $21.00, suggesting a potential upside of 177.78%. Given Evaxion A/S's higher probable upside, equities research analysts plainly believe Evaxion A/S is more favorable than Neuphoria Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Evaxion A/S 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Neuphoria Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders & institutionals hold more shares of EVAX or NEUP? 11.0% of Evaxion A/S shares are owned by institutional investors. Comparatively, 15.9% of Neuphoria Therapeutics shares are owned by institutional investors. 41.6% of Evaxion A/S shares are owned by company insiders. Comparatively, 0.7% of Neuphoria Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has stronger valuation & earnings, EVAX or NEUP? Evaxion A/S has higher revenue and earnings than Neuphoria Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEvaxion A/S$3.34M1.06-$10.57M-$1.16-2.19Neuphoria Therapeutics$10K1,421.28-$15.49MN/AN/A Is EVAX or NEUP more profitable? Neuphoria Therapeutics has a net margin of 0.00% compared to Evaxion A/S's net margin of -316.03%. Neuphoria Therapeutics' return on equity of 0.00% beat Evaxion A/S's return on equity.Company Net Margins Return on Equity Return on Assets Evaxion A/S-316.03% -532.72% -78.32% Neuphoria Therapeutics N/A N/A N/A Which has more risk & volatility, EVAX or NEUP? Evaxion A/S has a beta of 0.12, suggesting that its stock price is 88% less volatile than the S&P 500. Comparatively, Neuphoria Therapeutics has a beta of 0.5, suggesting that its stock price is 50% less volatile than the S&P 500. SummaryNeuphoria Therapeutics beats Evaxion A/S on 7 of the 13 factors compared between the two stocks. Get Evaxion A/S News Delivered to You Automatically Sign up to receive the latest news and ratings for EVAX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EVAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EVAX vs. The Competition Export to ExcelMetricEvaxion A/SMEDICAL INFO SYS IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.74M$2.00B$5.62B$9.30BDividend YieldN/AN/A4.25%4.03%P/E Ratio-2.1934.2528.5719.58Price / Sales1.0615.19424.2194.37Price / CashN/A54.7436.0257.93Price / Book-2.158.258.135.54Net Income-$10.57M-$62.39M$3.24B$257.73M7 Day Performance2.42%-0.28%2.03%0.95%1 Month Performance-8.30%11.94%8.29%10.68%1 Year Performance-83.87%7.07%28.40%15.67% Evaxion A/S Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EVAXEvaxion A/S2.7913 of 5 stars$2.54-4.9%$10.00+293.7%-83.8%$3.74M$3.34M-2.1960NEUPNeuphoria Therapeutics2.2209 of 5 stars$7.16+0.4%$21.00+193.3%N/A$13.40M$10K0.00N/AME23andMeN/A$0.50-35.3%N/A-94.8%$13.36M$208.78M-0.03770Gap DownHigh Trading VolumeATHAAthira Pharma3.458 of 5 stars$0.33-2.9%$11.25+3,308.1%-87.9%$13.27MN/A-0.1640Positive NewsIBIOiBio1.2733 of 5 stars$0.78+5.9%$4.30+448.0%-68.9%$12.96M$375K0.00100MTVAMetaVia1.7408 of 5 stars$0.62-4.0%$7.50+1,105.6%N/A$12.69MN/A0.008ALVRAlloVirN/A$2.50-2.3%N/A-86.8%$12.61MN/A-0.12110High Trading VolumeSONNSonnet BioTherapeutics3.7412 of 5 stars$4.73+20.7%$20.00+322.8%+38.3%$12.41M$20K0.0010Trending NewsGap DownHigh Trading VolumeNXTCNextCure4.3506 of 5 stars$0.44+1.2%$3.50+693.5%+197.0%$12.22MN/A-0.2590Analyst ForecastLPTXLeap Therapeutics2.2261 of 5 stars$0.28-2.6%$3.38+1,089.2%-86.0%$12.07MN/A-0.1740Positive NewsGap DownIMCCIM Cannabis0.1599 of 5 stars$3.30+11.5%N/A+34.8%$11.97M$39.44M-5.16340 Related Companies and Tools Related Companies Neuphoria Therapeutics Competitors 23andMe Competitors Athira Pharma Competitors iBio Competitors MetaVia Competitors AlloVir Competitors Sonnet BioTherapeutics Competitors NextCure Competitors Leap Therapeutics Competitors IM Cannabis Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EVAX) was last updated on 7/15/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredHere's the last trade you should make before heading out for the weekend tomorrow.Make this one trade at 2:59 PM on Friday afternoon, and you'll thank me on Monday morning.Timothy Sykes | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evaxion A/S - Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Evaxion A/S With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free EVAX Stock Alerts